Stayble Therapeutics (4K4) Stock Overview
A clinical pharmaceutical company, developing an injection-based treatments for disc herniation. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
4K4 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
Stayble Therapeutics AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 0.023 |
| 52 Week High | SEK 0.041 |
| 52 Week Low | SEK 0.0024 |
| Beta | -0.88 |
| 1 Month Change | 618.75% |
| 3 Month Change | 54.36% |
| 1 Year Change | -43.63% |
| 3 Year Change | -77.11% |
| 5 Year Change | -96.82% |
| Change since IPO | -97.09% |
Recent News & Updates
Recent updates
Shareholder Returns
| 4K4 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 1.8% | -1.0% | -1.0% |
| 1Y | -43.6% | 34.9% | -2.2% |
Return vs Industry: 4K4 underperformed the German Pharmaceuticals industry which returned 22.3% over the past year.
Return vs Market: 4K4 underperformed the German Market which returned 0.2% over the past year.
Price Volatility
| 4K4 volatility | |
|---|---|
| 4K4 Average Weekly Movement | 377.6% |
| Pharmaceuticals Industry Average Movement | 6.0% |
| Market Average Movement | 5.4% |
| 10% most volatile stocks in DE Market | 12.8% |
| 10% least volatile stocks in DE Market | 2.7% |
Stable Share Price: 4K4's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 4K4's weekly volatility has increased from 166% to 378% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 2 | Andreas Gerward | www.staybletherapeutics.se |
Stayble Therapeutics AB (publ) a clinical pharmaceutical company, developing an injection-based treatments for disc herniation. It develops STA363, an injection into the disc that targets chronic low back and leg pain. The company was incorporated in 2015 and is based in Gothenburg, Sweden.
Stayble Therapeutics AB (publ) Fundamentals Summary
| 4K4 fundamental statistics | |
|---|---|
| Market cap | €1.21m |
| Earnings (TTM) | -€985.39k |
| Revenue (TTM) | n/a |
Is 4K4 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4K4 income statement (TTM) | |
|---|---|
| Revenue | -SEK 17.00k |
| Cost of Revenue | SEK 0 |
| Gross Profit | -SEK 17.00k |
| Other Expenses | SEK 10.73m |
| Earnings | -SEK 10.75m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.17 |
| Gross Margin | 100.00% |
| Net Profit Margin | 63,211.76% |
| Debt/Equity Ratio | 0% |
How did 4K4 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/04 04:26 |
| End of Day Share Price | 2026/05/29 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Stayble Therapeutics AB (publ) is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.